Debut Plus

₹2,415

▼ -19.97 -0.82%

As of 10 Sept 2026 · delayed

NSE Listed

Glenmark Pharmaceuticals Ltd. (GLENMARK)

Volume: 2,62,107Avg Vol 1W: 3,62,917.6Avg Vol 1M: 5,21,877.9552W Range:₹1,792.6₹2,537.6
NSE BSE www.glenmarkpharma.com AI Report
Key Ratios
Checked 10h ago
Market Cap₹68,157 Cr
Current Price₹2,415
Previous Close₹2,434.97
High / Low (52w)₹2,537.6 / ₹1,792.6
Volume2,62,107
Avg Vol (1W)3,62,917.6
Avg Vol (1M)5,21,877.95
Stock P/E21.84
Book Value₹372.47
Dividend Yield20%
ROE28.08%
ROA9.03%
Revenue (TTM)₹17,443 Cr
Revenue Growth12.8%
Profit Margin10.22%
Total Debt₹513 Cr
Shares Outstanding28 Cr
Face Value₹1
EPS (TTM)₹110.59
P/B6.48
Debt / Equity0.16
50 DMA₹2,314.02
200 DMA₹2,180.58
Day change-0.82%
Price Chart
₹2,415▲ 13.33% · 1Y
₹2515₹181061.7L
2025-09-10
2026-09-10

20-day avg volume: 5.2L shares

Pros
  • Healthy return on equity of 28.1%.
  • Pays a dividend yield of 20.0%.
  • Company is almost debt-free.
  • Net profit is growing year over year.
Quarterly Results
MetricSept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Revenue₹3,434 Cr₹3,388 Cr₹3,256 Cr₹3,264 Cr₹6,047 Cr₹3,901 Cr₹3,771 Cr₹4,018 Cr
EBITDA₹521 Cr₹509 Cr₹448 Cr₹477 Cr₹2,419 Cr₹760 Cr₹804 Cr₹697 Cr
Net Profit₹354 Cr₹348 Cr₹5 Cr₹47 Cr₹610 Cr₹403 Cr₹301 Cr₹483 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Mar 2026Jun 2026
Revenue₹13,435 Cr₹2,009 Cr₹2,395 Cr₹1,539 Cr₹2,360 Cr₹2,147 Cr₹17,443 Cr₹2,435 Cr
EBITDA₹1,979 Cr₹373 Cr₹740 Cr₹49 Cr₹546 Cr₹279 Cr₹4,460 Cr₹666 Cr
Net Profit₹1,047 Cr₹148 Cr₹330 Cr₹-739 Cr₹282 Cr₹-74 Cr₹1,362 Cr₹736 Cr
EPS37.11—————48.24—
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹13,289 Cr₹14,685 Cr₹15,604 Cr₹17,083 Cr₹19,372 Cr₹14,359 Cr₹16,050 Cr₹19,908 Cr
Total Liabilities₹7,684 Cr₹8,615 Cr₹8,539 Cr₹7,645 Cr₹9,532 Cr₹6,511 Cr₹7,200 Cr₹9,396 Cr
Equity₹5,605 Cr₹6,070 Cr₹7,064 Cr₹9,438 Cr₹9,839 Cr₹7,848 Cr₹8,849 Cr₹10,512 Cr
Total Debt————————
Cash Flow
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹1,767 Cr₹1,859 Cr₹1,641 Cr₹1,667 Cr₹1,266 Cr₹782 Cr₹-147 Cr₹4,228 Cr
Investing₹-699 Cr₹-784 Cr₹-675 Cr₹-333 Cr₹-528 Cr₹4,561 Cr₹2 Cr₹-1,283 Cr
Financing₹-739 Cr₹-445 Cr₹-442 Cr₹-520 Cr₹-77 Cr₹-3,906 Cr₹787 Cr₹-2,709 Cr
Free Cash Flow₹1,767 Cr₹1,859 Cr₹1,641 Cr₹1,667 Cr₹1,266 Cr₹782 Cr₹-147 Cr₹4,228 Cr
Shareholding
Promoter 46.65% Institutions 39.5% Public 13.85%
Efficiency & Working Capital
ROCE32.7%
Interest Coverage21.4
Dividend Payout—
Debtor Days107 d
Inventory Days74 d
Payable Days80 d
Cash Conversion Cycle100 d
Working Capital Days180 d
Shareholding Details

As of 2026-06-30

Promoter46.7%
FII20.9%
DII18.6%
Institutions39.5%
Public13.8%
Promoter Pledge0%
No. of Shareholders2,11,418
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters46.6%46.6%46.6%46.6%46.6%46.6%46.6%46.6%46.6%46.7%46.7%46.7%
FIIs24.8%23.7%21.4%21%23.1%23.5%23.2%20.6%20.7%19.2%20.3%20.9%
DIIs10.3%10.9%13.4%13.9%13.2%13.8%14.6%17.6%18.6%20.1%19.3%18.6%
Public18.2%18.7%18.6%18.4%17.1%16%15.6%15.1%14%14.1%13.7%13.8%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders2,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,1052,11,418
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202603————
Major Shareholders (>1%)
NameCategoryStakeShares
Saldanha Family TrustShareholding of Promoter and Promoter Group45.4%12.82 Cr
Hdfc Mutual Fund - Hdfc Mid-cap FundPublic Shareholding6.2%1.76 Cr
Government Pension Fund GlobalPublic Shareholding3.9%1.10 Cr
Amansa Holdings Private LimitedPublic Shareholding2.2%62,51,753
Invesco India Contra FundPublic Shareholding2.2%62,17,592
Bandhan Nifty 200 Momentum 30 Index FundPublic Shareholding1.3%36,02,621
Uti Multi Cap FundPublic Shareholding1.2%32,58,742
Blanche Elizabeth SaldanhaShareholding of Promoter and Promoter Group0.4%11,14,327
Glenn Mario SaldanhaShareholding of Promoter and Promoter Group0.4%10,11,644
Cherylann Maria PintoShareholding of Promoter and Promoter Group0.3%7,63,915
Robin Joseph PintoShareholding of Promoter and Promoter Group0.2%4,99,500
Neha SaldanhaShareholding of Promoter and Promoter Group0%26,000
Board of Directors
NameDesignationYear
Glenn SaldanhaChairman / Executive Director / M D / Promoter2026
Cheryl PintoExecutive Director (Corporate)2026
Anurag MantriExecutive Director & Group CFO2026
Sona Saira RamasastryIndependent Non Exe. Director2026
Dipankar BhattacharjeeIndependent Non Exe. Director2026
V R IyerIndependent Non Exe. Director2026
Pradeep Kumar SinhaIndependent Non Exe. Director2026
Patricia AndrewsIndependent Non Exe. Director2026
B E SaldanhaNon Executive Director2026
Rashmi Khandelwal.Company Secretary / Compliance Officer2026
Segments — Product
SegmentRevenueShare
Pharmaceutical Products₹0 Cr—
Segments — Geography
RegionRevenueShare
India₹3,546 Cr42%
North America₹1,869 Cr22.1%
Europe₹1,496 Cr17.7%
Rest of the World₹1,529 Cr18.1%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2026₹12372828
Corporate Actions
TypeDateValueRemark
forthcoming2026-08-31Dividend (2.5/- per share)Final
forthcoming2026-08-31Dividend—
dividend2026-08-31₹2.5 (250%)Final
forthcoming2026-07-31Board Meetings—
dividend2025-10-03₹2.5 (250%)Interim
dividend2025-09-15₹2.5 (250%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
202617,90600471917,971
20261,82800001,828
20261,7870047191,853
Insider / Designated-Person Trades

10 recent disclosure(s)

Mr. Praveen D KurkalDisposal · 500
Mr. Praveen D KurkalDisposal · 1,000
Mr. Praveen D KurkalDisposal · 1,000
ROBIN PINTOAcquisition · 250
SRIDHAR GORTHIDisposal · 559
NEHA SALDANHAAcquisition · 20,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Market17/06/2025 · 3,57,499
Company Information
Incorporated1977
ChairmanGlenn Saldanha
AuditorWalker Chandiok & Co LLP
Investor Email[email protected]
🌐 www.glenmarkpharma.com ↗

📍 B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

GKB Ophthalmics Ltd.GK Energy LimitedGujarat Kidney & Super Speciality Ltd.GKW LimitedGland Pharma LimitedGlaxosmithkline Pharmaceuticals Ltd.Gujarat Lease Financing LimitedGlobal Education LimitedGlobale Tessile LimitedGlobal Pet Industries Ltd.Global Vectra Helicorp Ltd.Globe Enterprises (India) Ltd.All “G” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search